Patent · US Active

Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency

US8349319B2 · kind B2 · utility

25Cited by

14References

26Claims

0Family size

Assignees

Mount Sinai School of Medicine · US
Genzyme Corporation · US

Inventors

Edward H. Schuchman · Haworth, US
Robert J. Desnick · New York, US
Gerald F. Cox · Needham, US
Laura P. Andrews · Bolton, US
James Murray · Oak Lawn, US

Key dates

Filing date	Aug 28, 2010
Grant date	Jan 8, 2013
Priority date	—
Expiry date	Mar 25, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Y301/04012
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to dose escalation enzyme replacement therapy using acid sphingomyelinase (ASM) for the treatment of human subjects having acid sphingomyelinase deficiency (ASMD), and, in particular, patients with non-neurological manifestations of Niemann-Pick Disease (NPD), and in certain embodiments, NPD type B.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.